Posted by Michael Wonder on 25 Sep 2020
FDA approves first drug to treat group of rare blood disorders in nearly 14 years
25 September 2020 - Today, the U.S. FDA approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease.
The new indication for Nucala is the first approval for hypereosinophilic syndrome patients in nearly 14 years.
Nucala was evaluated in a randomised, double-blind, multicenter, placebo-controlled trial in 108 patients with hypereosinophilic syndrome.
